Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
Yu Akazawa(University of Fukui), Tetsuya Nakatsura(Unknown), Toshiaki Yoshikawa(Aichi Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Toshiyoshi Fujiwara(Okayama University), Manami Shimomura(National Cancer Center Hospital East), Mari Takahashi(Chiba Cancer Center), Yasunari Nakamoto(University of Fukui), Shoichi Mizuno(Shizuoka Cancer Center)
Cited by 16
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178